Sandbox Mati: Difference between revisions
Mati Cohen (talk | contribs) No edit summary |
Mati Cohen (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
the PDB file [http://www.proteopedia.org/wiki/index.php/2yxj 2yxj]shows the structure of Bcl-Xl and ABT 737. ABT 737 is a sub nano Molar inhibitor of Bcl-Xl. It binds Bcl-xl in the same position as BAK does as can be seen in [http://www.proteopedia.org/wiki/index.php/1bxl 1bxl]. | the PDB file [http://www.proteopedia.org/wiki/index.php/2yxj 2yxj]shows the structure of Bcl-Xl and ABT 737. ABT 737 is a sub nano Molar inhibitor of Bcl-Xl. It binds Bcl-xl in the same position as BAK does as can be seen in [http://www.proteopedia.org/wiki/index.php/1bxl 1bxl]. | ||
Interestingly the interface of Bcl-Xl is almost symmetric. There are <scene name='43/437742/2yxj_arg/2'>two positively charged residues</scene> Arg 100 and Arg 139. | Interestingly the interface of Bcl-Xl is almost symmetric. There are <scene name='43/437742/2yxj_arg/2'>two positively charged residues</scene> Arg 100 and Arg 139. | ||
<scene name='43/437742/2yxj_glu/1'>two | <scene name='43/437742/2yxj_glu/1'>two negativly charged residues</scene> Glu 96 and Glu 129. | ||
Revision as of 20:37, 27 August 2013
Bcl-Xl is a member of the Bcl-2 family . This family consists of pro-apoptotic and anti-apoptotic members. Bcl-Xl(in the image)
|
,an anti apoptotic protein, binds pro apoptotic proteins like BAK and BAD thus inhibiting program cell death. Many cancer cells overexpress at least one of the anti-apoptotic members of this family , thus escaping apoptosis . Therefore these proteins are important targets for the development of new anti-cancer drugs.
the PDB file 2yxjshows the structure of Bcl-Xl and ABT 737. ABT 737 is a sub nano Molar inhibitor of Bcl-Xl. It binds Bcl-xl in the same position as BAK does as can be seen in 1bxl. Interestingly the interface of Bcl-Xl is almost symmetric. There are two positively charged residues Arg 100 and Arg 139. two negativly charged residues Glu 96 and Glu 129.
